Skip to main content
Finanzoo GmbH Finanzoo GmbH

Dexcom Value Stock - Dividend - Research Selection

Dexcom

ISIN: US2521311074 , WKN: A0D9T1
Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.


Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet

Description of the company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,

NEWS


Jim Cramer on DexCom: “It’s Too Rich a Stock”

2025-12-13
DexCom, Inc. (NASDAQ:DXCM) is one of the stocks on Jim Cramer’s radar recently. A caller asked if they should buy, sell, or hold the stock during the lightning round. In response, Cramer said: “You know, it’s too rich a stock, and I do think the GLP-1s are going to have such a dramatic effect on […]
Yahoo

Lightning Round: MercadoLibre is 'such a good company', says Jim Cramer

2025-12-11
'Mad Money' host Jim Cramer weighs in on stocks including: MercadoLibre, NRGEnergy, AST SpaceMobile, Dexcom, and Bank of Nova Scotia.
CNBC

Cramer's Lightning Round: MercadoLibre is a buy

2025-12-11
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
CNBC

High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth

2025-12-11
Touchstone Mid Cap Growth Fund outperformed the Russell Midcap® Growth Index. Click here to uncover sector drivers, top holdings, and future strategy.
SeekingAlpha

DLocal And 2 Other Stocks That May Be Priced Below Intrinsic Value

2025-12-10
As the United States market remains mixed ahead of a highly anticipated Federal Reserve decision on interest rates, investors are keenly observing how these shifts might impact stock valuations. In this environment, identifying stocks that may be priced below their intrinsic value can offer opportunities for those looking to capitalize on potential market inefficiencies.
Yahoo

3 Prominent Stocks Estimated To Be Trading At Up To 38.4% Below Intrinsic Value

2025-12-10
As U.S. investors keenly await the Federal Reserve's decision on interest rates, major indices like the S&P 500 have recently pulled back after nearing record highs, reflecting a cautious market sentiment. In such an environment, identifying stocks trading below their intrinsic value can present opportunities for those looking to capitalize on potential undervaluation amidst broader economic uncertainties.
Yahoo

3 Stocks Estimated To Be Undervalued In December 2025

2025-12-09
As the Federal Reserve meeting unfolds and major indices like the Dow Jones, S&P 500, and Nasdaq show modest gains, investors are keenly observing how potential interest rate cuts might influence market dynamics. In this environment of cautious optimism and strategic shifts, identifying undervalued stocks becomes crucial for those looking to capitalize on potential market inefficiencies.
Yahoo

3 Stocks Estimated To Be Trading Below Their Intrinsic Value By Up To 46.3%

2025-12-09
As the U.S. stock market navigates a period of uncertainty with investors closely watching the Federal Reserve's upcoming decision on interest rates, major indices like the S&P 500 have recently pulled back after nearing record highs. In this environment, identifying stocks trading below their intrinsic value can be particularly appealing to investors seeking potential opportunities amidst broader market fluctuations.
Yahoo

Discover 3 Stocks Priced Below Estimated Value

2025-12-08
As the U.S. stock market navigates a period of volatility with major indices like the Dow Jones and S&P 500 experiencing fluctuations ahead of a critical Federal Reserve decision on interest rates, investors are keenly watching for opportunities amidst these shifts. In this environment, identifying stocks that are priced below their estimated value can offer potential advantages, as they may present opportunities for growth when market conditions stabilize or improve.
Yahoo

Freshworks And Two More Stocks Estimated To Be Trading Below Fair Value

2025-12-08
As U.S. stocks rise on hopes of a Federal Reserve rate cut, the market's attention is keenly focused on inflation data and major corporate deals like Netflix's acquisition of Warner Bros. Discovery. In such an environment, identifying undervalued stocks can be crucial for investors looking to capitalize on potential opportunities, as these stocks may offer significant value relative to their current market prices amidst shifting economic conditions.
Yahoo